Bowel cancer cells can ‘shapeshift' to enable aggressive spread, research finds
A study by the Cancer Research UK Scotland Centre and the University of Edinburgh found a key step in some aggressive forms of bowel cancer involved cancer cells losing their identity, known as cellular plasticity.
Researchers found the disease can spread when colonic cells shed their identity and resemble squamous cells which form skin, or resemble muscle.
Bowel cancer is the second most common cause of cancer deaths in the UK. It claims the lives of 16,800 people in Britain, including 1,700 in Scotland, every year and is increasingly being diagnosed in younger people internationally.
A recent study by the American Cancer Society published in The Lancet Oncology showed early-onset bowel cancer rates in adults aged 25-49 are rising in 27 of 50 countries studied, and increasing faster in young women in Scotland and England than in young men.
Scotland is disproportionately affected with around 4,000 people diagnosed each year overall, according to Cancer Research UK.
Bowel cancer cells were found to have 'shapeshifted' into skin cells, which are shown in brown (Dr Kevin Myant/PA)
The latest study found bowel cancer cells can adapt to resemble skin cells, which can tolerate much harsher day-to-day conditions due to their role and position protecting the outside of the body, and also muscle cells, both of which are more 'robust'.
Cellular plasticity was found to be an important element in bowel cancer metastasis – when it spreads and becomes harder to treat.
Researchers hope identifying this and preventing it could help make current treatments more effective and stop the disease from spreading.
The study also examined a particular gene called Atrx which was already associated with aggressive forms of bowel cancer.
Using mice and human tissue samples, researchers found the loss of this gene resulted in increased metastatic tumours which spread from the bowel to the liver, lymph nodes and the diaphragm.
Key to the ability of these cells to spread is that they shed their identity of colonic cells and resembled squamous cells which form skin, or cells that resemble muscle.
The paper, Loss Of Colonic Fidelity Enables Multilineage Plasticity And Metastasis, is published in Nature. The research received funding from the Medical Research Council and the European Research Council.
Dr Kevin Myant, of the Institute of Genetics and Cancer at the University of Edinburgh and the Cancer Research UK Scotland Centre, said 'With more and more younger people being diagnosed with bowel cancer, it's vital we understand how this disease grows and develops.
'Our research has discovered one way that aggressive bowel cancer is able to spread is by 'shapeshifting' to resemble skin or muscle cells rather than bowel cancer cells.
'This finding will hopefully allow us to develop new treatments to stop these cells changing and prevent the cancer spreading, when it becomes much harder to treat.'
Lead researcher Dr Patrizia Cammareri said: 'Skin cells can tolerate much harsher day-to-day conditions than other types of cells – due to their role and position protecting the outside of the body – so this may be a strategy to help the bowel cancer cells become more robust and enable them to spread around the body.
'Metastasis is a leading cause of cancer death and a key focus for cancer research, so this finding could be pivotal in halting the progression of aggressive cancer and providing better outcomes for patients.'
Cancer Research UK director of research, Dr Catherine Elliott, said: 'Diagnosing and treating cancer early and preventing spread to other parts of the body offers the best chance of a positive outcome for patients so research like this, which could lead to new ways to stop that spread, offers great hope.
'Bowel cancer is of increasing concern globally, which is why we invested £5.5 million to the CRC-STARS initiative (Colorectal Cancer – Stratification of Therapies through Adaptive Responses) jointly led by our Cancer Research UK Scotland Institute, which will bring together more than 40 bowel cancer experts, including researchers who worked on this project, to find new and kinder ways to tackle this disease.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 hours ago
- The Independent
More testing needed for genetic cancer risk as too many women ‘missed', experts say
A new study has revealed that families of some cancer patients are being denied the opportunity to learn about their potential cancer risk due to inconsistencies in genetic testing. Academics have warned that the absence of adequate testing for Lynch syndrome is leaving some cancer patients unaware of their risk of developing other cancers. Lynch syndrome, a rare hereditary condition, elevates the risk of cancers of the bowel, womb, and ovaries. It arises from a gene mutation affecting DNA error correction during replication, potentially leading to uncontrolled cell growth. NHS guidelines stipulate that patients with bowel or womb cancer should undergo tumour assessments for Lynch syndrome markers. The identification of these markers should prompt a referral for genetic testing, confirming the diagnosis and enabling access to support and guidance regarding cancer risks for both the patients and their families. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. They found that 91 per cent of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64 per cent) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48 per cent of those eligible went on to get the test. Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
Powys County Times
2 hours ago
- Powys County Times
Women with genetic cancer risk being ‘missed' due to testing gaps
Families of some cancer patients are being denied the chance to find out about their cancer risk due to gaps in genetic testing, a new study has suggested. A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have it. — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected.
South Wales Guardian
3 hours ago
- South Wales Guardian
Women with genetic cancer risk being ‘missed' due to testing gaps
A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
